
ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH
From HCPLive Podcasts by HCPLive.com
February 18, 2026 · 7 min
About this episode
Alan Buchman discusses the challenges of defining short bowel syndrome and the adoption of new ICD-10 codes to improve clarity in clinical practice.
Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology. In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications. His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice. Key Interview Time Stamps 0:00:00 What prompted this analysis of ICD code adoption in short bowel syndrome? 0:01:17 Key findings 0:03:33 Understanding reasons for variability in code adoption 0:04:36 The potential benefits of improved coding accuracy
People in this episode
Guest: Alan Buchman Md Msph
Topics covered
- ICD-10
- short bowel syndrome
- intestinal failure
- gastroenterology
- healthcare coding
Keywords
- ICD-10-CM codes
- World Health Organization
- disease burden
- clinical practice
- nutrition science
Mentioned in this episode
Places: US
More episodes of HCPLive Podcasts
- Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
- Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
- Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
- Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
- Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
- Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min
Explore listener stats, chart rankings, contacts and more on the HCPLive Podcasts podcast page.